PolyPeptide Group AG
Symboli: PPGN.SW
SIX
30.85
CHFMarkkinahinta tänään
-20.2164
P/E-suhde
-0.4777
PEG-suhde
1.02B
MRK Cap
- 0.00%
DIV Tuotto
PolyPeptide Group AG (PPGN-SW) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 208.66 | 95.7 | 37.5 | 136.3 | ||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.net-receivables | 279.04 | 101.1 | 49.1 | 67.8 | ||||||
balance-sheet.row.inventory | 564.08 | 128.5 | 145.1 | 113 | ||||||
balance-sheet.row.other-current-assets | 71.69 | 1.3 | 19.8 | 14.5 | ||||||
balance-sheet.row.total-current-assets | 1123.47 | 326.6 | 251.6 | 331.6 | ||||||
balance-sheet.row.property-plant-equipment-net | 1190.14 | 324.1 | 297.3 | 235.4 | ||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.intangible-assets | 63.7 | 16.5 | 15.9 | 14.3 | ||||||
balance-sheet.row.goodwill-and-intangible-assets | 63.7 | 16.5 | 15.9 | 14.3 | ||||||
balance-sheet.row.long-term-investments | 13.32 | 5.2 | 2.8 | 3.5 | ||||||
balance-sheet.row.tax-assets | 42.61 | 16.7 | 8.3 | 10.3 | ||||||
balance-sheet.row.other-non-current-assets | -25.92 | 0 | -8.3 | -10.3 | ||||||
balance-sheet.row.total-non-current-assets | 1283.86 | 362.5 | 315.9 | 253.2 | ||||||
balance-sheet.row.other-assets | 25.92 | 0 | 8.3 | 10.3 | ||||||
balance-sheet.row.total-assets | 2433.25 | 689.1 | 575.8 | 595 | ||||||
balance-sheet.row.account-payables | 160.69 | 60.9 | 45.9 | 28.5 | ||||||
balance-sheet.row.short-term-debt | 111.1 | 45.7 | 3.6 | 3.1 | ||||||
balance-sheet.row.tax-payables | 17.52 | 9.3 | 4.9 | 7.6 | ||||||
balance-sheet.row.long-term-debt-total | 97 | 68 | 9.4 | 10.3 | ||||||
Deferred Revenue Non Current | 47.26 | 23.2 | 7.5 | 9.2 | ||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 8.59 | - | - | - | ||||||
balance-sheet.row.other-current-liab | 237.3 | 1.4 | 50.1 | 75.5 | ||||||
balance-sheet.row.total-non-current-liabilities | 160.46 | 131.4 | 9.4 | 10.3 | ||||||
balance-sheet.row.other-liabilities | 146.11 | 0 | 48.6 | 59.6 | ||||||
balance-sheet.row.capital-lease-obligations | 87.25 | 23.3 | 21.2 | 18 | ||||||
balance-sheet.row.total-liab | 818.72 | 307.9 | 154.1 | 173.9 | ||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.common-stock | 1.21 | 0.3 | 0.3 | 0.3 | ||||||
balance-sheet.row.retained-earnings | 775.36 | 165.1 | 214.1 | 196 | ||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 74.69 | 23 | 17.7 | 13.2 | ||||||
balance-sheet.row.other-total-stockholders-equity | 763.27 | 192.7 | 189.5 | 211.6 | ||||||
balance-sheet.row.total-stockholders-equity | 1614.53 | 381.2 | 421.7 | 421.2 | ||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 2433.25 | 689.1 | 575.8 | 595 | ||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.total-equity | 1614.53 | 381.2 | 421.7 | 421.2 | ||||||
balance-sheet.row.total-liabilities-and-total-equity | 2433.25 | - | - | - | ||||||
Total Investments | 13.32 | 5.2 | 2.8 | 3.5 | ||||||
balance-sheet.row.total-debt | 232.77 | 113.7 | 21.2 | 18 | ||||||
balance-sheet.row.net-debt | 24.11 | 18 | -16.3 | -118.3 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -43.67 | -51.4 | 7.8 | 47.3 | ||||||
cash-flows.row.depreciation-and-amortization | 49.47 | 30.5 | 24 | 18.7 | ||||||
cash-flows.row.deferred-income-tax | 46.42 | 3.1 | 13.2 | 28.7 | ||||||
cash-flows.row.stock-based-compensation | 2.05 | 0.8 | 1.2 | 1.2 | ||||||
cash-flows.row.change-in-working-capital | -29.34 | 46.2 | -14.3 | -29.9 | ||||||
cash-flows.row.account-receivables | -10.56 | 0 | 18.8 | -12.2 | ||||||
cash-flows.row.inventory | -17.62 | 15.5 | -33.1 | -17.7 | ||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-working-capital | -1.16 | 30.7 | 0 | 0 | ||||||
cash-flows.row.other-non-cash-items | 63.45 | 7.3 | -26.3 | -8.6 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 41.95 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -128 | -56.7 | -75.1 | -74 | ||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-investing-activites | -9.95 | -2.8 | -3.3 | -6.9 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | -137.95 | -59.5 | -78.4 | -80.8 | ||||||
cash-flows.row.debt-repayment | -3.51 | -55.2 | -3.3 | -41.4 | ||||||
cash-flows.row.common-stock-issued | 13.79 | 0 | 17.2 | 182.1 | ||||||
cash-flows.row.common-stock-repurchased | -13.93 | 0 | -13.9 | -5.5 | ||||||
cash-flows.row.dividends-paid | -9.67 | 0 | -9.7 | -135.3 | ||||||
cash-flows.row.other-financing-activites | 71.01 | 139.7 | -17.2 | 130.9 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 57.68 | 84.5 | -26.9 | 130.9 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | -2.27 | -3.3 | 1.1 | 11.7 | ||||||
cash-flows.row.net-change-in-cash | -40.6 | 58.2 | -98.8 | 119.1 | ||||||
cash-flows.row.cash-at-end-of-period | 208.66 | 95.7 | 37.5 | 136.3 | ||||||
cash-flows.row.cash-at-beginning-of-period | 249.25 | 37.5 | 136.3 | 17.2 | ||||||
cash-flows.row.operating-cash-flow | 41.95 | 36.5 | 5.5 | 57.4 | ||||||
cash-flows.row.capital-expenditure | -128 | -56.7 | -75.1 | -74 | ||||||
cash-flows.row.free-cash-flow | -86.05 | -20.2 | -69.6 | -16.6 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 601.35 | 320.4 | 281 | 282.1 | ||||||
income-statement-row.row.cost-of-revenue | 544.59 | 315.7 | 229 | 182.4 | ||||||
income-statement-row.row.gross-profit | 56.76 | 4.6 | 52 | 99.7 | ||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.research-development | 2.71 | - | - | - | ||||||
income-statement-row.row.selling-general-administrative | 70.54 | - | - | - | ||||||
income-statement-row.row.selling-and-marketing-expenses | 8.96 | - | - | - | ||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.operating-expenses | 99.79 | 41.1 | 42.3 | 37 | ||||||
income-statement-row.row.cost-and-expenses | 644.37 | 356.8 | 271.3 | 219.5 | ||||||
income-statement-row.row.interest-income | 8.77 | 0.1 | 2.1 | 2.8 | ||||||
income-statement-row.row.interest-expense | 0 | 5.6 | 2.1 | 2.8 | ||||||
income-statement-row.row.selling-and-marketing-expenses | 8.96 | - | - | - | ||||||
income-statement-row.row.total-other-income-expensenet | -29.37 | -21.8 | -5 | -7.6 | ||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.total-operating-expenses | -29.37 | -21.8 | -5 | -7.6 | ||||||
income-statement-row.row.interest-expense | 0 | 5.6 | 2.1 | 2.8 | ||||||
income-statement-row.row.depreciation-and-amortization | 42.05 | 30.5 | 20.5 | 16.1 | ||||||
income-statement-row.row.ebitda-caps | 20.74 | - | - | - | ||||||
income-statement-row.row.operating-income | -21.3 | -36.5 | 12.5 | 67.4 | ||||||
income-statement-row.row.income-before-tax | -50.68 | -58.2 | 7.6 | 59.8 | ||||||
income-statement-row.row.income-tax-expense | 12.19 | -6.8 | 0.2 | 12.6 | ||||||
income-statement-row.row.net-income | -43.67 | -51.4 | 7.8 | 47.3 |
Usein kysytty kysymys
Mikä on PolyPeptide Group AG (PPGN.SW) taseen loppusumma?
PolyPeptide Group AG (PPGN.SW) kokonaisvarat ovat 689088000.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on 320372000.000.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.015.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on -0.498.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on -0.161.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on -0.106.
Mikä on PolyPeptide Group AG (PPGN.SW) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on -51440000.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 113662000.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 41110000.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 95706000.000.